Orion Corporation

Gerd Wohlfahrt

Arja Karjalainen

Patrik Holm

Olli Törmäkangas

Petteri Rummakko

Harri Salo

David Din Belle

Anniina Vesalainen

Sirpa Rasku

Iisa Höglund

Eija Tiainen

Pekka Pietikäinen

Pia Koivikko

Mikko Passiniemi

Subhendu Mukherjee

Tero Linnanen

Matti Vaismaa

Ravi Kotrabasaiah Ujjinamatada

Arto Tolvanen

Arto Karljalainen

Mikko Kalervo Mäkelä

Srinivas Nanduri

Srinivasan Rajagopalan

Anu Moilanen

Susanta Samajdar

Anssi Haikarainen

Jari Ratilainen

Paavo Huhtala

Terhi Heikkinen

Chandrasekhar Abbineni

Pranab Kumar Patra

Mikko Mäkelä

Pekka Kallio

Arputharaj Ebenezer Martin

Rathna Durga Ramasubramanian

Pia Knuuttila

Emilia Väisänen

Olli Toermaekangas

Iisa Hoeglund

Olli Tormakangas

Lisa HÖGLUND

Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors

The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof. 

Androgen receptor modulating compounds

A compound of formula (I), wherein R, R, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (1) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Protein kinase inhibitors

The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2&#x2032;-one derivatives of formula (I)  in which Cy, R, R, R, L, and m have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.

Spiro[cyclobutane-1,3'-indolin]-2&#x2032;-one derivatives as bromodomain inhibitors

CYP17 inhibitors/antiandrogens

The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.

A compound of formula (I), wherein R, R, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Compounds of formula (I) or (II) wherein R, R, R, R, R, R', R, R&#x2032;, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

Androgen receptor modulating carboxamides

2,3-dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases

2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases

Growing community of inventors

Helsinki, Finland

Gerd Wohlfahrt